永顺生物:2024年报净利润0.4亿 同比下降31.03%

Financial Performance - The company's basic earnings per share decreased to 0.1500 yuan in 2024 from 0.2100 yuan in 2023, representing a decline of 28.57% [1] - The net profit for 2024 was 0.4 billion yuan, down 31.03% from 0.58 billion yuan in 2023 [1] - Operating revenue fell to 2.69 billion yuan in 2024, a decrease of 14.33% compared to 3.14 billion yuan in 2023 [1] - The return on equity (ROE) dropped to 6.08% in 2024 from 8.61% in 2023, marking a decline of 29.38% [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 14.1447 million shares, accounting for 17.6% of the circulating shares, which is a decrease of 1.1042 million shares from the previous period [1] - Guangdong Yongshun Biopharmaceutical Co., Ltd. remains unchanged with 360.00 million shares, representing 4.48% of total share capital [2] - Cai Jianping's holdings decreased by 22.00 million shares, now totaling 319.97 million shares, or 3.98% of total share capital [2] Dividend Distribution - The company announced a dividend distribution plan of 1.3 yuan per share (including tax) [2]